Analytical Data
-
Gene name
KCNK13
- Application
-
Alternative Names
KCNK13；Potassium channel subfamily K member 13
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9HB14
-
Expression Region
1-408aa
-
AA Sequence
MAGRGFSWGPGHLNEDNARFLLLAALIVLYLLGGAAVFSALELAHERQAKQRWEERLANFSRGHNLSRDELRGFLRHYEEATRAGIRVDNVRPRWDFTGAFYFVGTVVSTIGFGMTTPATVGGKIFLIFYGLVGCSSTILFFNLFLERLITIIAYIMKSCHQRQLRRRGALPQESLKDAGQCEVDSLAGWKPSVYYVMLILCTASILISCCASAMYTPIEGWSYFDSLYFCFVAFSTIGFGDLVSSQNAHYESQGLYRFANFVFILMGVCCIYSLFNVISILIKQSLNWILRKMDSGCCPQCQRGLLRSRRNVVMPGSVRNRCNISIETDGVAESDTDGRRLSGEMISMKDLLAANKASLAILQKQLSEMANGCPHQTSTLARDNEFSGGVGAFAIMNNRLAETSGDR
-
Molecular Weight
51.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KCNK13, also known as TASK-3, is a member of the two-pore domain potassium channel family that plays a crucial role in regulating neuronal excitability and maintaining potassium ion homeostasis. The channel is expressed in various tissues, including the brain, heart, and kidney, and its activity is modulated by several factors such as pH, lipids, and specific pharmacological agents. The investigation of KCNK13 recombinant protein has garnered significant attention due to its potential implications in various physiological and pathological processes, including pain signaling, mood disorders, and respiratory control. Studies have demonstrated that KCNK13 is involved in the modulation of synaptic activity and neuronal firing, making it a potential target for therapeutic interventions. Additionally, mutations or dysregulation of KCNK13 have been linked to cardiac arrhythmias and other disorders, underscoring the need for a deeper understanding of its functional mechanisms. By producing recombinant KCNK13, researchers can explore its structural and functional properties, screen for specific inhibitors or activators, and investigate its role in disease models. This research not only enhances our knowledge of potassium channels but also provides insights into the broader context of ion channel pharmacology and potential drug development strategies aimed at treating conditions related to KCNK13 dysregulation. Understanding KCNK13's mechanisms and interactions could pave the way for novel therapeutic approaches that target ion channelopathies and improve patient outcomes.
